We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Viridian Therapeutics Inc | NASDAQ:VRDN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 21.56 | 15.50 | 22.03 | 3 | 10:05:47 |
Guggenheim 4th Annual Neuro/Immunology Conference
Format: | Fireside Chat |
Date: | November 15, 2022 |
Time: | 1:35 p.m. ET |
Webcast link: | Registration link |
The live webcast and a replay of the fireside chats can also be accessed under “Events” in the Investors section of the Viridian Therapeutics website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian TherapeuticsVice President, Investor Relations& Corporate Communications617-272-4691IR@viridiantherapeutics.com
1 Year Viridian Therapeutics Chart |
1 Month Viridian Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions